{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022891","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-05-14T12:45:38+00:00","discovered_at":"2026-05-14T12:50:00.284142+00:00","generated_at":"2026-05-14T12:50:38.658955+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AIM ImmunoTech reports Ampligen pancreatic cancer data: OS improvement 7.2 months vs historical controls","bullets":["Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.","DURIPANC Phase 2 with AstraZeneca's Imfinzi interim data suggests improved QoL; mid-2026 report due June.","Stratified by Neutrophil/Lymphocyte ratio <4.5: PFS 17.7 months (+9.1 mo) and OS 34.8 months (+22.3 mo).","CA 19-9 <1000 subgroup: PFS 13.1 months (+4.5 mo) and OS 24.1 months (+11.6 mo)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022891","json":"https://secwatch.observer/filing/0001493152-26-022891.json","markdown":"https://secwatch.observer/filing/0001493152-26-022891.md","text":"https://secwatch.observer/filing/0001493152-26-022891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226022891/0001493152-26-022891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226022891/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:50:38.658955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}